FORM NO. MGT-7

Form language

(iii)

[Pursuant to sub-Section(1) of section 92 of the Companies Act, 2013 and sub-rule (1) of rule 11of the Companies (Management and Administration) Rules, 2014]



AAACG2207L

Annual Return

(other than OPCs and Small **Companies**)

Refer the instruction kit for filing the form.						
I. REGISTRATION AND OTHER DETAILS						
(i) * Corporate Identification Number (CIN) of the company	L24299MH1977PLC019982	Pre-fi				
Global Location Number (GLN) of the company						
* Permanent Account Number (PAN) of the company	AAACG2207I					

(ii) (a) Name of the company GLENMARK PHARMACEUTICAL

(b) Registered office address

B-2MAHALAXMI CHAMBERS22 BHULABHAI DESAI ROAD MAHALAXMI MUMBAI Maharashtra 400026	
c) *e-mail ID of the company	complianceofficer@glenmarkp
d) *Telephone number with STD code	02240189999
e) Website	www.glenmarkpharma.com
Date of Incorporation	18/11/1977

Type of the Company Category of the Company Sub-category of the Company (iv) **Public Company** Company limited by shares Indian Non-Government company

(v) Whether company is having share capital	Yes	○ No	
(vi) *Whether shares listed on recognized Stock Exchange(s)	Yes	O No	

(a) Details of stock exchanges where shares are listed

*Number of business activities

S. No.	Stock Exchange Name	Code
1	BSE Limited	1
2	National Stock Exchange of India Limited	1,024

(b) CIN of the Registrar and	d Transfer Agent		U72400TG	52017PLC117649	Pre-fill
Name of the Registrar and	d Transfer Agent				_
KFIN TECHNOLOGIES LIMITI	ED				
Registered office address	of the Registrar and Tr	ransfer Agents			_
Selenium, Tower B, Plot No- Financial District, Nanakram					
(vii) *Financial year From date	01/04/2021	(DD/MM/YYYY)) To date	31/03/2022	(DD/MM/YYYY)
(viii) *Whether Annual general r	meeting (AGM) held	Y	'es 🔾	No	
(a) If yes, date of AGM	27/09/2022				
(b) Due date of AGM	30/09/2022				
(c) Whether any extension	for AGM granted) Yes	No	
II. PRINCIPAL BUSINESS	S ACTIVITIES OF	THE COMPAN	ΙY		

S.No	Main Activity group code		Business Activity Code	,	% of turnover of the company
1	С	Manufacturing	C6	Chemical and chemical products, pharmaceuticals, medicinal chemical and	100

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (INCLUDING JOINT VENTURES)

*No. of Companies for which information is to be given 40 Pre-fill All

S.No	Name of the company	CIN / FCRN	Holding/ Subsidiary/Associate/ Joint Venture	% of shares held
1	GLENMARK LIFE SCIENCES LIM	L74900PN2011PLC139963	Subsidiary	82.84
2	Glenmark Holding S.A.		Subsidiary	100

3	Ichnos Sciences SA (Formerly k	Subsidiary	100
4	Glenmark Pharmaceuticals Eur	Subsidiary	100
5	Glenmark Pharmaceuticals S.R	Subsidiary	100
6	Glenmark Pharmaceuticals SK,	Subsidiary	100
7	Glenmark Pharmaceuticals SP	Subsidiary	100
8	Glenmark Pharmaceuticals Inc	Subsidiary	100
9	Glenmark Therapeutics Inc.	Subsidiary	100
10	Glenmark Farmaceutica Ltda	Subsidiary	100
11	Glenmark Generics S.A	Subsidiary	100
12	Glenmark Pharmaceuticals Me	Subsidiary	100
13	Glenmark Pharmaceuticals Per	Subsidiary	100
14	Glenmark Pharmaceuticals Col	Subsidiary	100
15	Glenmark Uruguay S.A.	Subsidiary	100
16	Glenmark Pharmaceuticals Ver	Subsidiary	100
17	Glenmark Dominicana SRL	Subsidiary	100
18	Glenmark Pharmaceuticals Egy	Subsidiary	100
19	Glenmark Pharmaceuticals FZE	Subsidiary	100
20	Glenmark Impex L.L.C	Subsidiary	100
21	Glenmark Philippines Inc.	Subsidiary	100
22	Glenmark Pharmaceuticals (Ni	Subsidiary	100
23	Glenmark Pharmaceuticals Ma	Subsidiary	100
24	Glenmark Pharmaceuticals (Au	Subsidiary	100
25	Glenmark South Africa (pty) Lt	Subsidiary	100
26	Glenmark Pharmaceuticals Sou	Subsidiary	100
27	Glenmark Pharmaceuticals (Th	Subsidiary	49

28	Glenmark Pharmaceuticals B.V	Subsidiary	100
29	Glenmark Arzneimittel Gmbh	Subsidiary	100
30	Glenmark Pharmaceuticals Car	Subsidiary	100
31	Glenmark Pharmaceuticals Ker	Subsidiary	100
32	Viso Farmaceutica S.L., Spain	Subsidiary	100
33	Glenmark Specialty SA	Subsidiary	100
34	Glenmark Pharmaceuticals Dis	Subsidiary	100
35	Glenmark Pharmaceuticals No	Subsidiary	100
36	Glenmark Ukraine LLC	Subsidiary	100
37	Glenmark Pharmaceuticals Ecu	Subsidiary	100
38	Glenmark Pharmaceuticals Sin	Subsidiary	100
39	Ichnos Sciences Biotherapeutic	Subsidiary	100
40	Ichnos Sciences Inc., USA	Subsidiary	100

IV. SHARE CAPITAL, DEBENTURES AND OTHER SECURITIES OF THE COMPANY

(i) *SHARE CAPITAL

(a) Equity share capital

Particulars	Authorised capital	Issued capital	Subscribed capital	Paid up capital
Total number of equity shares	2,370,000,000	282,168,156	282,168,156	282,168,156
Total amount of equity shares (in Rupees)	2,370,000,000	282,168,156	282,168,156	282,168,156

Number of classes 1

Class of Shares	Authoricad	Icabilai	Subscribed capital	Paid up capital
Number of equity shares	2,370,000,000	282,168,156	282,168,156	282,168,156
Nominal value per share (in rupees)	1	1	1	1
Total amount of equity shares (in rupees)	2,370,000,000	282,168,156	282,168,156	282,168,156

(b) Preference share capital

Particulars	Authorised capital	Issued capital	Subscribed capital	Paid-up capital
Total number of preference shares	4,000,000	0	0	0
Total amount of preference shares (in rupees)	400,000,000	0	0	0

N	ıım	her	of c	lasses
ıν	ulli	ושט	UI C	iasses

1

Class of shares	Authorised capital	Issued capital	Subscribed capital	Paid up capital
Number of preference shares	4,000,000	0	0	0
Nominal value per share (in rupees)	100	100	100	100
Total amount of preference shares (in rupees)	400,000,000	0	0	0

(c) Unclassified share capital

Particulars	Authorised Capital
Total amount of unclassified shares	0

(d) Break-up of paid-up share capital

Class of shares	Nı	ımber of sh	ares	Total nominal amount	Total Paid-up amount	Total premium
Equity shares	Physical	DEMAT	Total			
At the beginning of the year	1,007,544	281,160,612	282168156	282,168,156	282,168,15	
Increase during the year	0	35,808	35808	0	0	0
i. Pubic Issues	0	0	0	0	0	
ii. Rights issue	0	0	0	0	0	0
iii. Bonus issue	0	0	0	0	0	0
iv. Private Placement/ Preferential allotment	0	0	0	0	0	0
v. ESOPs	0	0	0	0	0	0
vi. Sweat equity shares allotted	0	0	0	0	0	
vii. Conversion of Preference share	0	0	0	0	0	0
viii. Conversion of Debentures	0	0	0	0	0	0
ix. GDRs/ADRs	0	0	0	0	0	

x. Others, specify		35,808	35808			
Dematerialisation of physical Shares		33,000	33000			
Decrease during the year	35,808	0	35808	0	0	0
i. Buy-back of shares	0	0	0	0	0	0
ii. Shares forfeited	0	0	0	0	0	
iii. Reduction of share capital	0	0	0	0	0	
iv. Others, specify	35,808		35808			
Dematerialisation of physical Shares	35,606		33000			
At the end of the year	971,736	281,196,420	282168156	282,168,156	282,168,15	
Preference shares						
At the beginning of the year	0	0	0	0	0	
Increase during the year	0	0	0	0	0	0
i. Issues of shares	0	0	0	0	0	
ii. Re-issue of forfeited shares	0	0	0	0	0	0
iii. Others, specify						
Decrease during the year	0	0	0	0	0	0
i. Redemption of shares	0	0	0	0	0	0
ii. Shares forfeited	0	0	0	0	0	0
iii. Reduction of share capital	0	0	0	0	0	0
iv. Others, specify						
At the end of the year	0	0	0	0	0	

ISIN of the equity shares of the company

NF	935	A೧٬	1035

(ii) Details of stock split/consolidation during the year (for each class of shares)

_			
)			
•			

Class of shares			(i)	(ii)			(iii)	
Before split /	Number of shares							
Consolidation	Face value per share							
After split /	Number of shares							
Consolidation	Face value per share							
						l		
• •	es/Debentures Trans t any time since the					cial ye	ear (or in the case	
Nil								
[Details being prov	vided in a CD/Digital Med	ia]	\bigcirc	Yes 🔾	No	\bigcirc	Not Applicable	
Separate sheet att	ached for details of trans	fers	\circ	Yes 🔘	No			
Note: In case list of trans Media may be shown.	sfer exceeds 10, option fo	or submis	ssion as a separa	te sheet atta	chment o	r subm	ission in a CD/Digital	
Date of the previous	s annual general meetir	ıg						
Date of registration	of transfer (Date Month	Year)						
Type of transfe	er	1 - Ec	quity, 2- Prefere	nce Shares	,3 - Deb	enture	es, 4 - Stock	
Number of Shares/ Units Transferred	Debentures/			per Share/ ire/Unit (in F	Rs.)			
Ledger Folio of Transferor								
Transferor's Name								
	Surname		middle	name		f	irst name	
Ledger Folio of Trar	nsferee							

Transferee's Name								
	Surna	ime		middle name first name				
Date of registration o	of transfer (Da	te Month Year)						
Type of transfer 1 - Equity, 2- Preference Shares,3 - Debentures, 4 - Stock								
Number of Shares/ Debentures/ Units Transferred			Amount per Share/ Debenture/Unit (in Rs.)					
Ledger Folio of Trans	sferor							
Transferor's Name								
	Surna	ime		middle name	first name			
Ledger Folio of Transferee								
Transferee's Name								
	Surna	ime		middle name	first name			

(iv) *Debentures (Outstanding as at the end of financial year)

Particulars	Number of units	Nominal value per unit	Total value
Non-convertible debentures	0	0	0
Partly convertible debentures	0	0	0
Fully convertible debentures	0	0	0
Total			0

Details of debentures

Class of debentures	Outstanding as at the beginning of the year	_	Decrease during the year	Outstanding as at the end of the year
Non-convertible debentures	0	0	0	0
Partly convertible debentures	0	0	0	0
Fully convertible debentures	0	0	0	0

Nominal Value of

each Unit

(v) Securities (other than shares and debentures) Number of

Securities

U	
Paid up Value of each Unit	Total Paid up Value

Total					
V *Turnovor a	nd not worth	of the company	v (as dofined i	n the Compan	ine Act 2013)

(i) Turnover

Type of Securities

81,415,812,794

Total Nominal

Value

(ii) Net worth of the Company

167,385,866,456

VI. (a) *SHARE HOLDING PATTERN - Promoters

S. No.	Category	Equ	ity	Preference	
		Number of shares	Percentage	Number of shares	Percentage
1.	Individual/Hindu Undivided Family				
	(i) Indian	3,375,751	1.2	0	
	(ii) Non-resident Indian (NRI)	0	0	0	
	(iii) Foreign national (other than NRI)	0	0	0	
2.	Government				
	(i) Central Government	0	0	0	
	(ii) State Government	0	0	0	
	(iii) Government companies	0	0	0	
3.	Insurance companies	0	0	0	
4.	Banks	0	0	0	
5.	Financial institutions	0	0	0	

6.	Foreign institutional investors	0	0	0	
7.	Mutual funds	0	0	0	
8.	Venture capital	0	0	0	
9.	Body corporate (not mentioned above)	0	0	0	
10.	Others Saldanha Family Trust	128,241,936	45.45	0	
	Total	131,617,687	46.65	0	0

Total number of shareholders (promoters)

(b) *SHARE HOLDING PATTERN - Public/Other than promoters

S. No.	Category	Equ	ity	Prefere	ence
		Number of shares	Percentage	Number of shares	Percentage
1.	Individual/Hindu Undivided Family				
	(i) Indian	0	0	0	
	(ii) Non-resident Indian (NRI)	2,684,802	0.95	0	
	(iii) Foreign national (other than NRI)	106,539	0.04	0	
2.	Government				
	(i) Central Government	0	0	0	
	(ii) State Government	0	0	0	
	(iii) Government companies	0	0	0	
3.	Insurance companies	0	0	0	
4.	Banks	595,194	0.21	0	
5.	Financial institutions	650,000	0.23	0	
6.	Foreign institutional investors	66,645	0.02	0	
7.	Mutual funds	17,425,807	6.18	0	
8.	Venture capital	0	0	0	
9.	Body corporate (not mentioned above)	3,470,924	1.23	0	
10.	Others Trusts,AIF,Resident Individu	125,550,558	44.49	0	

		Total	150,	,550,469	53.35	0	0
Total nun	nber of s	hareholders (other than pron	noters)	310,510			
Total num Other than		nareholders (Promoters+Publ ters)		310,516			
(c) *Detail	s of Fore	eign institutional investors' (F	IIs) hol	ding shar	res of the compa	any	1
Name of the	FII		Date of Incorpo		Country of Incorporation	Number of shares held	% of shares held
India Value II	nvestmen	Kanjurmarg East, Mumbai, 400042			IN	66,645	0.02

VII. *NUMBER OF PROMOTERS, MEMBERS, DEBENTURE HOLDERS (Details, Promoters, Members (other than promoters), Debenture holders)

Details	At the beginning of the year	At the end of the year
Promoters	6	6
Members (other than promoters)	250,845	310,510
Debenture holders	0	0

VIII. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

(A) *Composition of Board of Directors

Category		directors at the g of the year		ectors at the end ne year		shares held by the end of year
	Executive	Non-executive	Executive	Non-executive	Executive	Non-executive
A. Promoter	2	1	2	1	0.62	0.39
B. Non-Promoter	1	7	1	7	0	0.04
(i) Non-Independent	1	0	1	0	0	0
(ii) Independent	0	7	0	7	0	0.04
C. Nominee Directors representing	0	0	0	0	0	0
(i) Banks & FIs	0	0	0	0	0	0
(ii) Investing institutions	0	0	0	0	0	0
(iii) Government	0	0	0	0	0	0
(iv) Small share holders	0	0	0	0	0	0

(v) Others	0	0	0	0	0	0
Total	3	8	3	8	0.62	0.43

Number of Directors and Key managerial personnel (who is not director) as on the financial year end date

13

(B) (i) *Details of directors and Key managerial personnel as on the closure of financial year

Name	DIN/PAN	Designation	Number of equity share(s) held	Date of cessation (after closure of financial year : If any)
Glenn Mario Saldanha	00050607	Managing Director	983,439	
Cherylann Maria Pinto	00111844	Whole-time directo	758,485	
V.S. Mani	01082878	Whole-time directo	600	
Rajesh Vasudeo Desai	00007960	Director	109,167	
Blanche Elizabeth Salda	00007671	Director	1,110,327	
Sridhar Gorthi	00035824	Director	0	
Devendra Raj Mehta	01067895	Director	0	
Brian William Tempest	00101235	Director	0	
Bernard Hubert Munos	05198283	Director	0	
Sona Saira Ramasastry	08398547	Director	0	
Dipankar Bhattacharjee	08770548	Director	0	
Harish Vinayak Kuber	ABRPK8790R	Company Secretar	0	
V.S. Mani	AAGPM5727N	CFO	600	

(ii) Particulars of change in director(s) and Key managerial personnel during the year

0

Name	beginning / during	ichange in designation/	Nature of change (Appointment/ Change in designation/ Cessation)

IX. MEETINGS OF MEMBERS/CLASS OF MEMBERS/BOARD/COMMITTEES OF THE BOARD OF DIRECTORS

A. MEMBERS/CLASS /REQUISITIONED/NCLT/COURT CONVENED MEETINGS

Number of meetings held

Type of meeting	Date of meeting	Total Number of Members entitled to attend meeting	Attendance Number of members % of total	
			attended	shareholding
Annual General Meeting	24/09/2021	332,808	115	46.29

B. BOARD MEETINGS

*Number of meetings held 5

S. No.	Date of meeting	Total Number of directors associated as on the date			
		of meeting	Number of directors attended	% of attendance	
1	16/04/2021	11	10	90.91	
2	28/05/2021	11	11	100	
3	13/08/2021	11	10	90.91	
4	12/11/2021	11	10	90.91	
5	11/02/2022	11	10	90.91	

C. COMMITTEE MEETINGS

Number of meetings held 25

S. No.			Total Number of Members as	Attendance		
		Date of meeting		Number of members attended	% of attendance	
1	Audit Committe	14/04/2021	3	3	100	
2	Audit Committe	27/05/2021	3	3	100	
3	Audit Committe	13/08/2021	3	3	100	
4	Audit Committe	11/11/2021	3	3	100	
5	Audit Committe	10/02/2022	3	3	100	
6	Stakeholder R	27/05/2021	3	3	100	
7	Stakeholder R	12/08/2021	3	2	66.67	
8	Stakeholder R	11/11/2021	3	3	100	
9	Stakeholder R	09/02/2022	3	3	100	
10	Risk Managerr		4	4	100	

D. *ATTENDANCE OF DIRECTORS

		Board Meetings			C	gs	Whether attended AGM	
S. No.	Name of the director	Number of Meetings which director was	Number of Meetings	% of attendance	Number of Meetings which director was	Number of Meetings	% of attendance	held on
		entitled to attend	attended	allendance	entitled to attend	attended	allendance	27/09/2022
								(Y/N/NA)
1	Glenn Mario S	5	5	100	12	12	100	Yes
2	Cherylann Ma	5	4	80	8	6	75	Yes
3	V.S. Mani	5	5	100	4	4	100	Yes
4	Rajesh Vasud	5	5	100	13	13	100	Yes
5	Blanche Elizat	5	3	60	0	0	0	Yes
6	Sridhar Gorthi	5	4	80	13	13	100	No
7	Devendra Raj	5	5	100	17	17	100	Yes
8	Brian William ⁻	5	5	100	0	0	0	Yes
9	Bernard Hube	5	5	100	0	0	0	Yes
10	Sona Saira Ra	5	5	100	8	8	100	Yes
11	Dipankar Bhat	5	5	100	4	4	100	Yes

X. *REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

Nil

Number of Managing Director, Whole-time Directors and/or Manager whose remuneration details to be entered

3

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1	Glenn Mario Saldan	Chairman & Mar	129,647,542	15,750,000	0	12,518,026	157,915,568
2	Cherylann Maria Pir	Executive Direct	37,656,978	4,620,000	0	4,319,597	46,596,575
3	V.S. Mani	Executive Direct	52,553,964	0	0	26,171,971	78,725,935
	Total		219,858,484	20,370,000	0	43,009,594	283,238,078

Number of CEO, CFO and Company secretary whose remuneration details to be entered

1

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1	Harish Vinayak Kub	Company Secre	3,924,673	0	0	823,001.89	4,747,674.89
	Total		3,924,673	0	0	823,001.89	4,747,674.89

S. No.	Name	Designation	Gross Salary	Commission	Stock Option/ Sweat equity	Others	Total Amount
1	Blanche Elizabeth S	Director	0	0	0	300,000	300,000
2	Rajesh Vasudeo De	Director	0	0	0	1,800,000	1,800,000
3	Sridhar Gorthi	Director	0	0	0	0	0
4	Devendra Raj Meht	Director	0	0	0	2,200,000	2,200,000
5	Brian William Temp	Director	0	0	0	500,000	500,000
6	Bernard Munos	Director	0	0	0	500,000	500,000
7	Sona Saira Ramasa	Director	0	0	0	1,300,000	1,300,000
8	Dipankar Bhattacha	Director	0	0	0	900,000	900,000
	Total		0	0	0	7,500,000	7,500,000

(I. MATTERS RELAT	ED TO CERTIFICAT	ION OF COMPLIAN	ICES AND DISCLOSU	RES	
* A. Whether the con provisions of the	mpany has made com e Companies Act, 201	npliances and disclos 3 during the year	sures in respect of appl	icable Yes	O No
B. If No, give reas	ons/observations				
	UNISHMENT - DETA		COMPANY/DIRECTOR	S/OFFICERS N	lil
Name of the company/ directors/ officers	Name of the court/ concerned Authority	Date of Order	Name of the Act and section under which penalised / punished		Details of appeal (if any) including present status
(B) DETAILS OF CO	MPOUNDING OF OF	FENCES N	il		
Name of the company/ directors/ officers	Name of the court/ concerned Authority	Date of Order	Name of the Act and section under which offence committed	Particulars of offence	Amount of compounding (in Rupees)

XIII. Whether complete list of sha	reholders, debenture holders has been enclosed as an attachment
Yes No	
(In case of 'No', submit the details s	separately through the method specified in instruction kit)
XIV. COMPLIANCE OF SUB-SECT	TION (2) OF SECTION 92, IN CASE OF LISTED COMPANIES
	mpany having paid up share capital of Ten Crore rupees or more or turnover of Fifty Crore rupees or in whole time practice certifying the annual return in Form MGT-8.
Name	S S Rauthan & Associates
Whether associate or fellow	
Certificate of practice number	3233
	ney stood on the date of the closure of the financial year aforesaid correctly and adequately. ed to the contrary elsewhere in this Return, the Company has complied with all the provisions of the
	Declaration
•	rectors of the company vide resolution no 24 dated 16/03/2022 and declare that all the requirements of the Companies Act, 2013 and the rules made thereunder
in respect of the subject matter of the	his form and matters incidental thereto have been compiled with. I further declare that:
	form and in the attachments thereto is true, correct and complete and no information material to orm has been suppressed or concealed and is as per the original records maintained by the company.
2. All the required attachmen	nts have been completely and legibly attached to this form.
Note: Attention is also drawn to punishment for fraud, punishme	the provisions of Section 447, section 448 and 449 of the Companies Act, 2013 which provide for nt for false statement and punishment for false evidence respectively.
To be digitally signed by	
Director	V S Digitally signed by V S MANI Date: 2022.11.07 17:35:11 +05'30'
DIN of the director	01082878
To be digitally signed by	HARISH VINAYAK VINAYAK KUBER VINATAK VINAT
Company Secretary	
Ocompany secretary in practice	
Membership number 10973	Certificate of practice number

List of attachments 1. List of share holders, debenture holders MGT-8-2022.pdf Attach Committe Meeting details as on 31032022 2. Approval letter for extension of AGM; Attach 3. Copy of MGT-8; Attach 4. Optional Attachement(s), if any Attach Remove attachment Prescrutiny Submit Check Form Modify

Attachments

This eForm has been taken on file maintained by the Registrar of Companies through electronic mode and on the basis of statement of correctness given by the company





Company Secretaries

Surjan Singh Rauthan
B.Com., F.C.S.

Form No. MGT-8

(Pursuant to section 92(2) of the Companies Act, 2013 and rule 11(2) of Companies (Management and Administration) Rules, 2014)

CERTIFICATE BY A COMPANY SECRETARY IN PRACTICE

We have examined the registers, records and books and papers of **Glenmark Pharmaceuticals Limited (the Company)** as required to be maintained under the Companies Act, 2013 (the Act) and the rules made thereunder for the financial year ended on 31st March, 2022. In our opinion and to the best of our information and according to the examinations carried out by us and explanations furnished to me by the Company, its officers and agents, we certify that

- A. The Annual Return states the facts as at the close of the aforesaid financial year correctly and adequately.
- B. During the aforesaid financial year, the Company has complied with provisions of the Act & Rules made thereunder as applicable to it, in respect of:
 - 1. Its status under the Act;
 - 2. Maintenance of registers/records & making entries therein within the prescribed time;
 - 3. (a) Filing of forms and returns as stated in the annual return, with the Registrar of Companies within the prescribed time.
 - (b) During the year under review, the Company has not filed any forms and returns as stated in the annual return with the Regional Director, Central Government, the Tribunal, Court or other authorities within the prescribed time;
 - 4. Calling/convening/holding meetings of Board of Directors, its committees, and the meetings of the members of the company on due dates as stated in the annual return in respect of which meetings, proper notices were given and the proceedings including the circular resolutions and resolutions passed by postal ballot, if any, have been properly recorded in the Minute Book/registers maintained for the purpose and the same have been signed.
 - 5. Closure of Register of Members/security holders as the case may be

Page 1 of 4

Practicing Since 1999



E-mail: ssrauthan@ssrgroupindia.in / ssrassociates@gmail.com • Website: www.ssrgroupindia.in





Company Secretaries

Surjan Singh Rauthan B.Com., F.C.S.

- Advances to its directors and/or persons or firms or companies referred in section 185 of the Act;
- Contracts/arrangements with related parties as specified in section 188 of the Act;
- (a) During the year under review, there was no issue or allotment or transfer or transmission of equity shares.
 - (b) During the year under review, there were no buy back of equity shares/ redemption of preference shares or debentures/ alteration or reduction of share capital/ conversion of shares/ securities and issue of security certificates.
- During the year under review, there was no transaction necessitating the Company to keep in abeyance the rights to dividend, rights shares and bonus shares pending registration of transfer of shares in compliance with the provisions of the Act;
- 10. Declaration/payment of dividend; transfer of unpaid/unclaimed dividend/other amounts as applicable to the Investor Education and Protection Fund in accordance with section 125 of the Act;
- 11. Signing of audited financial statement as per the provisions of section 134 of the Act and report of directors is as per sub-section (3), (4) and (5) thereof;
- 12. Constitution/appointment/re-appointments/retirement/filling-up casual vacancies/ disclosures of the Directors, Key Managerial Personnel and the remuneration paid to them;
- 13. Appointment/reappointment/filing-up casual vacancies of auditors as per the provisions of section 139 of the Act;
- 14. During the year under review, there were no approvals required to be taken from the Central Government, Tribunal Regional Director, Registrar, Court or such authorities.
- 15. During the year under review, the Company has not accepted/invited/renewed/re-paid any public deposits.

Page 2 of 4



Practicing Since 1999







Company Secretaries

Surjan Singh Rauthan B.Com., F.C.S.

- Borrowings from its directors, members, public financial institutions, banks and others and creation/modification/satisfaction of charges in that respect, wherever applicable;
- 17. Loans and investments or guarantees given or providing of securities to other bodies corporate or persons falling under the provisions of section 186 of the Act;
- During the year under review, the Company has not altered the provisions of the Memorandum and/or Articles of Association of the Company;

For S. S. Rauthan & Associates

Company Secretaries
Firm Registration No.:S1999MH026900

CS Surjan Singh Rauthan
Proprietor

FCS No. 4807

CP No. 3233

UDIN: F004807D001222298

Place: Mumbai

Date: 13/10/2022

This Report is to be read with my letter annexed as Appendix A, which forms an integral part of this report.



E-mail: ssrauthan@ssrgroupindia.in / ssrassociates@gmail.com • Website: www.ssrgroupindia.in





Company Secretaries

Surjan Singh RauthanB.Com., F.C.S.

APPENDIX 'A'

TO WHOM SO EVER IT MAY CONCERN

Our report of even date is to be read along with this letter.

- The responsibility of maintaining Secretarial record is of the management and based on our verification of aforesaid records, I have issued this Certificate.
- We are of the opinion that the audit practices and process adopted to obtain assurance about the correctness of the Secretarial records were reasonable for verification.
- We have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
- The management is responsible for compliances with corporate laws. Our examination was limited to the verification of aforesaid records and documents wherever required.
- The certificate is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For S. S. Rauthan & Associates

Company Secretaries

Firm Registration No.:S1999MH026900

CS Surjan Singh Rauthan

Proprietor

FCS No. 4807 CP No. 3233

UDIN: F004807D001222298

Place: Mumbai Date: 13/10/2022

Page 4 of 4





E-mail: ssrauthan@ssrgroupindia.in / ssrassociates@gmail.com • Website: www.ssrgroupindia.in

COMMITTEE MEETINGS

Number of Meetings held - 25

S. No.			Total Number of Members as	Attendance		
	Type of meeting	Date of meeting	on the date of the meeting	Number of members attended	% of attendance	
1	Audit Committee	14/04/2021	3	3	100	
2	Audit Committee	27/05/2021	3	3	100	
3	Audit Committee	13/08/2021	3	3	100	
4	Audit Committee	11/11/2021	3	3	100	
5	Audit Committee	10/02/2022	3	3	100	
6	Stakeholder Relationship Committee	27/05/2021	3	3	100	
7	Stakeholder Relationship Committee	12/08/2021	3	2	66.67	
8	Stakeholder Relationship Committee	11/11/2021	3	3	100	
9	Stakeholder Relationship Committee	09/02/2022	3	3	100	
10	Risk Management Committee	27/05/2021	4	4	100	
11	Risk Management Committee	12/08/2021	4	4	100	
12	Risk Management Committee	11/11/2021	4	4	100	
13	Risk Management Committee	11/02/2022	4	4	100	
14	Nomination and Remuneration Committee	28/05/2021	3	3	100	
15	Nomination and Remuneration Committee	12/08/2021	3	3	100	
16	Nomination and Remuneration Committee	12/11/2021	3	3	100	
17	Nomination and Remuneration Committee	09/02/2022	3	3	100	
18	Corporate Social Responsibility	27/05/2021	3	3	100	
19	Corporate Social Responsibility	12/08/2021	3	2	66.67	
20	Corporate Social Responsibility	09/11/2021	3	3	100	
21	Corporate Social Responsibility	10/02/2022	3	3	100	
22	Environmental, Social and Governance Committee	28/05/2021	3	3	100	



23	Environmental, Social and Governance Committee	13/08/2021	3	3	100
24	Environmental, Social and Governance Committee	12/11/2021	3	3	100
25	Environmental, Social and Governance Committee	10/02/2022	3	3	100

